Sarissa Capital Management’s Pacira BioSciences PCRX Stock Holding History

Sarissa Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-430,000	Closed	-$14.7M	–	13
2016 Q3	$14.7M	Sell	430,000 -223,000	-34%	-$8.74M	3.39%	5
2016 Q2	$22M	Buy	653,000 +120,800	+23%	+$5.94M	6.25%	5
2016 Q1	$28.2M	Hold	532,200	–	–	6.21%	6
2015 Q4	$40.9M	Buy	532,200 +152,200	+40%	+$8.62M	7.95%	6
2015 Q3	$15.6M	Buy	+380,000	New	+$23.3M	3.86%	8

Other funds holding PCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sarissa Capital Management's PCRX Position: Q4 2016 in Review

Sarissa Capital Management sold out of Pacira BioSciences (PCRX) in Q4 2016, closing a stake of 430,000 shares — an estimated $14.7M sold.

Sarissa Capital Management first reported a position in PCRX in Q3 2015 and held it in 5 quarters. The position peaked at $40.9M in Q4 2015. 182 funds tracked by Wall St. Rank hold PCRX as of Q4 2016.

Sarissa Capital Management reported no remaining Pacira BioSciences position as of Q4 2016 after selling out during the quarter.
Sarissa Capital Management sold 430,000 Pacira BioSciences shares in Q4 2016, an estimated $14.7M.
Sarissa Capital Management first reported a position in Pacira BioSciences in Q3 2015 and held it in 5 quarters.
Sarissa Capital Management's Pacira BioSciences position peaked at $40.9M in Q4 2015.
182 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2016.

Based on Sarissa Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.